Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, announced its participation in the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The company's presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET, through the conference portal and Lumos Pharma's website. No one-on-one meetings will be conducted during this event. Lumos Pharma focuses on therapeutics for rare diseases, with LUM-201 as its lead candidate for Pediatric Growth Hormone Deficiency.
- None.
- None.
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.
| H.C. Wainwright BioConnect 2021 Conference | |
| Date: | January 11, 2021 |
| What: | Lumos Pharma Presentation |
| A webcast of Lumos Pharma’s presentation will be available on-demand as of 6:00AM ET, Monday, January 11, 2021, through the H.C. Wainwright conference portal and on Lumos Pharma’s website under “Events & Presentations” in the Investors & Media section. The webcast will be available on Lumos Pharma’s website for 30 days. | |
No one-on-one meetings will be held at the presentation - only H.C. Wainwright BioConnect 2021 Conference. Investors are invited to contact Lumos Pharma Investor Relations directly to schedule one-on-one meetings with management.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
When is the H.C. Wainwright BioConnect 2021 Conference for LUMO?
What is LUM-201 being developed for?
How can I watch Lumos Pharma's presentation at the conference?
Will there be one-on-one meetings during the conference for LUMO?
What is the focus of Lumos Pharma's research?
